Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024Business Wire • 06/01/24
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)Business Wire • 05/29/24
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsBusiness Wire • 05/15/24
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)Seeking Alpha • 05/14/24
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/08/24
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First QuarterInvestors Business Daily • 05/08/24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookBusiness Wire • 05/08/24
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaBusiness Wire • 05/08/24
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 05/03/24
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsBusiness Wire • 05/02/24
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsBusiness Wire • 04/16/24
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaBusiness Wire • 04/11/24
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024Business Wire • 04/09/24